Vivimed Labs Limited (VIVIMEDLAB) AI Stock Analysis

1 Followers

Vivimed Labs Limited

(NSE:VIVIMEDLAB)

Select Model

Rating:46Neutral

Price Target:INR 6.00▲(2.04% Upside)

Action:reiterated

Date:08/27/26

The overall score is low because the company’s fundamentals are severely distressed, with steep multi-year revenue declines, sustained heavy losses, negative equity, and high leverage dominating the risk profile. Recent technical strength offers some support but is driven by a short-term, overextended move that may not be durable, while valuation remains weakly anchored given negative earnings and no dividend.

Positive Factors

Recent cash-flow improvementPositive operating and free cash flow in 2026 provides some internal funding support and is an improvement from negative cash flow in 2024–2025. If maintained, this could help the company meet obligations and support operations without relying entirely on external financing.

Negative Factors

Persistent revenue declineMulti-year revenue contraction indicates that the business has not sustained demand or commercial momentum across the reported period. Continued shrinking sales can reduce operating leverage, weaken customer scale, and make a durable return to profitability more difficult.

Vivimed Labs Limited (VIVIMEDLAB) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 457.68M
Dividend Yield: ―
Average Volume (3M): 16.54K
Price to Earnings (P/E): -0.3
Beta (1Y): 0.44
Revenue Growth: -39.80%
EPS Growth: -452.04%
Country: India
Employees: 586
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Vivimed Labs Limited Business Overview & Revenue Model

Company Description

Established in 1988 and headquartered in Hyderabad, India, Vivimed Labs Limited, along with its associated entities, is an international manufacturer and supplier of diverse products, including active pharmaceutical ingredients (APIs), finished drug...

Vivimed Labs Limited Financial Statement Overview

Summary

Financial performance is very weak, with revenue shrinking from 8.6 billion to 0.7 billion over FY 2021–2026, persistent operating and net losses, negative gross profit in the latest year, heavily negative equity and high debt, and only a small recent improvement in cash flow that is insufficient to offset the overall distressed condition.

Income Statement

8Very Negative

Balance Sheet

5Very Negative

Cash Flow

18Very Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	699.89M	699.89M	1.16B	1.49B	1.87B	2.37B
Gross Profit	-335.58M	-547.76M	77.98M	705.71M	-928.65M	838.04M
EBITDA	-1.46B	-1.46B	-86.77M	-246.69M	-1.86B	-67.91M
Net Income	-1.76B	-1.76B	-319.61M	-454.46M	-3.29B	-676.50M
Balance Sheet
Total Assets	7.53B	7.53B	9.21B	9.51B	9.88B	12.66B
Cash, Cash Equivalents and Short-Term Investments	13.56M	13.56M	7.08M	717.79M	37.62M	71.84M
Total Debt	3.97B	3.97B	3.76B	3.79B	3.81B	2.78B
Total Liabilities	9.64B	9.64B	9.56B	9.56B	9.49B	9.02B
Stockholders Equity	-2.11B	-2.11B	-351.69M	-54.61M	394.23M	3.64B
Cash Flow
Free Cash Flow	67.56M	67.56M	-86.28M	-260.30M	303.54M	-6.75B
Operating Cash Flow	77.03M	77.03M	-40.97M	-239.91M	138.12M	-6.58B
Investing Cash Flow	-9.47M	-9.47M	-45.31M	282.88M	-49.68M	5.23B
Financing Cash Flow	-61.07M	-61.07M	73.10M	-60.32M	-162.44M	-103.80M

Vivimed Labs Limited Technical Analysis

Technical Analysis SentimentNegative

Last Price5.88

Price Trends

50DMA6.23Negative

100DMA5.86Positive

200DMA6.44Negative

Market Momentum

MACD-0.04Positive

RSI39.41Neutral

STOCH10.48Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VIVIMEDLAB, the sentiment is Negative. The current price of 5.88 is below the 20-day moving average (MA) of 6.37, below the 50-day MA of 6.23, and below the 200-day MA of 6.44, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 39.41 is Neutral, neither overbought nor oversold. The STOCH value of 10.48 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:VIVIMEDLAB.

Vivimed Labs Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:VIVIMEDLAB against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:LAURUSLABS	77Outperform	INR 1.25T	93.66	―	0.09%	23.03%	95.69%
IN:NEULANDLAB	66Neutral	INR 249.35B	55.50	―	0.17%	50.46%	88.44%
IN:GRANULES	64Neutral	INR 197.69B	27.49	―	0.22%	21.75%	36.70%
IN:HIKAL	61Neutral	INR 26.37B	-556.58	―	0.27%	8.93%	-149.51%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:SOLARA	50Neutral	INR 30.25B	83.54	―	―	27.30%	456.80%
IN:VIVIMEDLAB	46Neutral	INR 496.65M	-0.25	―	―	-39.80%	-452.04%

* General Sector Average

Performance Comparison

IN:VIVIMEDLAB and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:VIVIMEDLAB	Vivimed Labs Limited	5.88	0.98	20.00%
IN:GRANULES	Granules India Limited	794.55	244.05	44.33%
IN:HIKAL	Hikal Limited	222.40	-11.99	-5.11%
IN:LAURUSLABS	Laurus Labs Ltd.	2306.10	1328.12	135.80%
IN:NEULANDLAB	Neuland Laboratories Ltd.	19614.30	2093.84	11.95%
IN:SOLARA	Solara Active Pharma Sciences Ltd.	645.40	80.65	14.28%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 27, 2026

Vivimed Labs Limited AI Stock Analysis